<DOC>
	<DOCNO>NCT01045577</DOCNO>
	<brief_summary>A double-blind , placebo-controlled , randomize , parallel-group study evaluate activity oral AB1010 adult patient moderate severe chronic plaque psoriasis</brief_summary>
	<brief_title>A Double-blind , Placebo-controlled , Randomized , Parallel-group Study Evaluate Activity Oral AB1010 Adults Patients With Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description>To evaluate activity oral AB1010 , administer two dose level 12 week patient moderate severe chronic plaque psoriasis , assess : ) Body Surface Area ( BSA ) , Psoriasis Area Severity Index ( PASI ) , Overall Lesion Severity ( OLS ) , Physician 's Global Assessment ( PGA ) Patient 's Global Psoriasis Assessment ( PGPA ) ii ) clinical biological safety parameter iii ) pharmacokinetic profile AB1010</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male female outpatient age 18 75 year chronic plaque psoriasis Plaque psoriasis cover ≥ 10 % BSA Disease duration ≥ 6 month PASI ≥ 12.0 screen Guttate , erythrodermic pustular psoriasis sole predominant form disease Clinically significant psoriasis flare screen time enrollment Systemic therapy psoriasis systemic immunosuppressive therapy indication within 28 day prior enrollment Topical treatment psoriasis within 14 day prior enrollment Use CYP3A4 moderate strong inhibitor within 4 week prior randomization Active current bacterial , viral ( include hepatitis B C , HIV , EBV , CMV , herpes zoster , herpes simplex ) , fungal , mycobacterium , protozoan , infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Severe Psoriasis</keyword>
	<keyword>Kinase Inhibitor</keyword>
	<keyword>Masitinib</keyword>
</DOC>